Cargando…
Danazol Treatment for Thrombocytopenia in Myelodysplastic Syndromes: Can an “Old-fashioned” Drug be Effective?
Autores principales: | Riva, Marta, Bosi, Alessandro, Rizzo, Lorenzo, Mazzon, Federico, Ferrari, Silvia, Lussana, Federico, Borin, Lorenza, Castelli, Andrea, Cairoli, Roberto, Barcellini, Wilma, Molteni, Alfredo, Fattizzo, Bruno |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047600/ https://www.ncbi.nlm.nih.gov/pubmed/36999006 http://dx.doi.org/10.1097/HS9.0000000000000867 |
Ejemplares similares
-
Hypoplastic Myelodysplastic Syndromes: Just an Overlap Syndrome?
por: Fattizzo, Bruno, et al.
Publicado: (2021) -
Novel Therapies for Unmet Clinical Needs in Myelodysplastic Syndromes
por: Cassanello, Giulio, et al.
Publicado: (2022) -
Mesenchymal Stem Cells in Aplastic Anemia and Myelodysplastic Syndromes: The “Seed and Soil” Crosstalk
por: Fattizzo, Bruno, et al.
Publicado: (2020) -
Cyclical Thrombocytopenia Synchronized With the Patient’s Menstrual Cycle Treated With Danazol
por: Menakuru, Sasmith R., et al.
Publicado: (2022) -
Pulmonary embolism in a patient with eltrombopag-treated aplastic anaemia and paroxysmal nocturnal haemoglobinuria clone during COVID-19 pneumonia
por: Alessandro, Bosi, et al.
Publicado: (2022)